Insider Transactions Reported by 18 Insiders of Bionano Genomics, Inc.

Symbol: BNGO on Nasdaq
Location: San Diego, CA

Quick Takeaways

BNGO - Bionano Genomics, Inc. has 18 insiders with reported activity on this page.
No net insider buy/sell flow is currently reported for the last year.
Recent transaction rows are available for direct filing-level review.

What Changed

No meaningful buy/sell imbalance is currently visible in the one-year window.
Activity will update as new Forms 3/4/5 are filed.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 07 Apr 2025.

Buys

Shares: 0

Insiders: 0

Sells

Shares: 0

Insiders: 0

Net

Shares: 0

Insiders: 0

Window (months)	Buy $	Sell $	Net $
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

Bionano Genomics, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Valuation	Report Date
Soheil Shams	Chief Informatics Officer	$3,217,163	Mixed	15 Feb 2022
Christopher P. Stewart	Chief Financial Officer	$180,810	Mixed	12 May 2023
Gulsen Kama	Chief Financial Officer	$20,320	Mixed	03 Jun 2024
R. Erik Holmlin	PRESIDENT AND CEO, Director	$1,822	Mixed	17 Feb 2026
Mark Oldakowski	Chief Operating Officer	$984	Mixed	17 Feb 2026
Alka Chaubey	Chief Medical Officer	$708	Mixed	17 Feb 2026
Jonathan Dixon V	General Counsel	$289	Mixed	17 Feb 2026
Mark Adamchak	Principal Accounting Officer	$286	Mixed	17 Feb 2026
Robert J. Priar	Chief Commercial Officer		Mixed	01 Jun 2021
Richard Shippy	Chief Business Officer		Mixed	15 Feb 2022
Vincent Jung-Fai Wong	Director		Mixed	18 Jun 2024
Hannah Mamuszka	Director		Mixed	11 Jun 2025
Yvonne Linney	Director		Mixed	11 Jun 2025
David L. Barker	Director		Mixed	11 Jun 2025
Albert Luderer	Director		Mixed	11 Jun 2025
Aleksandar Rajkovic	Director		Mixed	11 Jun 2025
Christopher J. Twomey	Director		Mixed	11 Jun 2025
Kristiina Vuori MD	Director		Mixed	11 Jun 2025

Top shareholders of Bionano Genomics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Soheil Shams	3/4/5	Chief Informatics Officer	— mixed-class rows	5,556,479 mixed-class rows	$3,217,163	—	15 Feb 2022	3/4/5
Lincoln Alternative Strategies LLC	13D/G	—	5.4%	525,000	$2,021,250	$0	17 Sep 2025	13D/G
INTRACOASTAL CAPITAL, LLC	13D/G	Mitchell P. Kopin	5%	508,415	$1,957,398	$0	16 Sep 2025	13D/G
CVI Investments, Inc.	13D/G	—	9.9%	1,129,411	$1,795,763	+$171,307	31 Dec 2025	13D/G
Lind Global Fund III LP	13D/G	—	9.4%	1,050,000	$1,669,500	+$851,703	31 Dec 2025	13D/G
Iroquois Capital Management, LLC	13D/G	Richard Abbe	5%	98,944	$1,088,384	$0	30 Sep 2025	13D/G
Ayrton Capital LLC	13D/G	—	10%	528,245	$903,140	$0	30 Sep 2025	13D/G
GSA CAPITAL PARTNERS LLP	13F	Company	3%	337,777	$517,000	—	31 Dec 2025	13F
DRW Securities, LLC	13F	Company	1.5%	168,453	$257,733	—	31 Dec 2025	13F
Christopher P. Stewart	3/4/5	Chief Financial Officer	— class O/S missing	281,373	$180,810	—	12 May 2023	3/4/5
VANGUARD GROUP INC	13F	Company	0.73%	82,307	$125,930	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.59%	66,766	$102,153	—	31 Dec 2025	13F
CARRET ASSET MANAGEMENT, LLC	13F	Company	0.39%	44,100	$67,473	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.36%	40,513	$61,985	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.33%	37,000	$56,610	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.2%	22,170	$33,920	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.18%	20,519	$31,394	—	31 Dec 2025	13F
FLAGSHIP HARBOR ADVISORS, LLC	13F	Company	0.06%	4,000	$28,440	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	— mixed-class rows	5,725 mixed-class rows	$28,295	—	31 Dec 2025	13F
R Squared Ltd	13F	Company	0.12%	13,771	$21,070	—	31 Dec 2025	13F
Gulsen Kama	3/4/5	Chief Financial Officer	— mixed-class rows	91,000 mixed-class rows	$20,320	—	03 Jun 2024	3/4/5
UBS Group AG	13F	Company	— mixed-class rows	9,697 mixed-class rows	$18,396	—	31 Dec 2025	13F
Engineers Gate Manager LP	13F	Company	0.09%	10,210	$15,621	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.09%	9,937	$15,204	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.08%	8,453	$12,933	—	31 Dec 2025	13F
OSAIC HOLDINGS, INC.	13F	Company	0.05%	5,731	$8,763	—	31 Dec 2025	13F
Federation Des Caisses Desjardins du Quebec	13F	Individual	— mixed-class rows	1,213 mixed-class rows	$8,578	—	31 Dec 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	— mixed-class rows	3,555 mixed-class rows	$5,489	—	31 Dec 2025	13F
GROUP ONE TRADING LLC	13F	Company	— mixed-class rows	1,382 mixed-class rows	$2,505	—	31 Dec 2025	13F
R. Erik Holmlin	3/4/5	PRESIDENT AND CEO, Director	— mixed-class rows	71,141 mixed-class rows	$1,822	—	17 Feb 2026	3/4/5
Concord Wealth Partners	13F	Company	0.01%	1,000	$1,530	—	31 Dec 2025	13F
ROYAL BANK OF CANADA	13F	Company	0%	100	$1,000	—	31 Dec 2025	13F
Mark Oldakowski	3/4/5	CHIEF OPERATING OFFICER	— mixed-class rows	28,632 mixed-class rows	$984	—	17 Feb 2026	3/4/5
Allworth Financial LP	13F	Company	— mixed-class rows	106 mixed-class rows	$721	—	31 Dec 2025	13F
Alka Chaubey	3/4/5	CHIEF MEDICAL OFFICER	— mixed-class rows	28,381 mixed-class rows	$708	—	17 Feb 2026	3/4/5
SBI Securities Co., Ltd.	13F	Company	0%	224	$343	—	31 Dec 2025	13F
Jonathan Dixon V	3/4/5	GENERAL COUNSEL	— mixed-class rows	26,380 mixed-class rows	$289	—	17 Feb 2026	3/4/5
Mark Adamchak	3/4/5	Principal Accounting Officer	— mixed-class rows	11,150 mixed-class rows	$286	—	17 Feb 2026	3/4/5
SSA SWISS ADVISORS AG	13F	Company	0%	37	$264	—	31 Dec 2025	13F
TD Waterhouse Canada Inc.	13F	Company	— mixed-class rows	23 mixed-class rows	$141	—	31 Dec 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	— mixed-class rows	31 mixed-class rows	$53	—	31 Dec 2025	13F
HHM Wealth Advisors, LLC	13F	Company	0%	6	$43	—	31 Dec 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	13	$20	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	11	$17	—	31 Dec 2025	13F
Activest Wealth Management	13F	Company	0%	3	$5	—	31 Dec 2025	13F
NATIONAL BANK OF CANADA /FI/	13F	Company	0%	2	$3	—	31 Dec 2025	13F
Ancora Advisors LLC	13F	Company	0%	1	$2	—	31 Dec 2025	13F
Aviso Financial Inc.	13F	Company	0%	1	$1	—	31 Dec 2025	13F
Richard Shippy	3/4/5	Chief Business Officer	— class O/S missing	550,000	—	—	15 Feb 2022	3/4/5
Robert J. Priar	3/4/5	Chief Commercial Officer	— class O/S missing	400,000	—	—	01 Jun 2021	3/4/5

Recent Insider Transactions by Companies or Individuals for Bionano Genomics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Shares	Shares Owned	Date	Ownership
Alka Chaubey	BNGO	Common Stock	Tax liability	-2.72%	-18	644	17 Feb 2026	Direct
Mark Adamchak	BNGO	Common Stock	Tax liability	-1.14%	-3	260	17 Feb 2026	Direct
Jonathan Dixon V	BNGO	Common Stock	Tax liability	-2.23%	-6	263	17 Feb 2026	Direct
Mark Oldakowski	BNGO	Common Stock	Tax liability	-2.19%	-20	895	17 Feb 2026	Direct
R. Erik Holmlin	BNGO	Common Stock	Tax liability	-2.99%	-51	1,657	17 Feb 2026	Direct
Mark Adamchak	BNGO	Stock Option (Right to Buy)	Award		10,890	10,890	02 Feb 2026	Direct
Jonathan Dixon V	BNGO	Stock Option (Right to Buy)	Award		26,117	26,117	02 Feb 2026	Direct
Alka Chaubey	BNGO	Stock Option (Right to Buy)	Award		27,737	27,737	02 Feb 2026	Direct
Mark Oldakowski	BNGO	Stock Option (Right to Buy)	Award		27,737	27,737	02 Feb 2026	Direct
R. Erik Holmlin	BNGO	Stock Option (Right to Buy)	Award		69,484	69,484	02 Feb 2026	Direct
Mark Oldakowski	BNGO	Common Stock	Tax liability	-6.06%	-59	915	11 Sep 2025	Direct
Alka Chaubey	BNGO	Common Stock	Tax liability	-7.15%	-51	662	11 Sep 2025	Direct
Christopher J. Twomey	BNGO	Stock Option (Right to Buy)	Award		2,775	2,775	11 Jun 2025	Direct
Kristiina Vuori MD	BNGO	Stock Option (Right to Buy)	Award		2,775	2,775	11 Jun 2025	Direct
Yvonne Linney	BNGO	Stock Option (Right to Buy)	Award		2,775	2,775	11 Jun 2025	Direct
Albert Luderer	BNGO	Stock Option (Right to Buy)	Award		2,775	2,775	11 Jun 2025	Direct
David L. Barker	BNGO	Stock Option (Right to Buy)	Award		2,775	2,775	11 Jun 2025	Direct
Hannah Mamuszka	BNGO	Stock Option (Right to Buy)	Award		2,775	2,775	11 Jun 2025	Direct
Aleksandar Rajkovic	BNGO	Stock Option (Right to Buy)	Award		2,775	2,775	11 Jun 2025	Direct
Mark Oldakowski	BNGO	Common Stock	Tax liability	-2.7%	-27	974	03 Jun 2025	Direct
Mark Adamchak	BNGO	Common Stock	Tax liability	-2.59%	-7	263	03 Jun 2025	Direct
Alka Chaubey	BNGO	Common Stock	Tax liability	-3.26%	-24	713	03 Jun 2025	Direct
R. Erik Holmlin	BNGO	Common Stock	Tax liability	-4.21%	-75	1,708	03 Jun 2025	Direct
Jonathan Dixon V	BNGO	Common Stock	Tax liability	-8.5%	-25	269	03 Jun 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.